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Abstract
Background: HIV-1 infects human astrocytes in vitro and in vivo but the frequency of infected cells
is low and its biological significance is unknown. In studies in vitro, recombinant gp120 alone can
induce profound effects on astrocyte biology, suggesting that HIV-1 interaction with astrocytes and
its functional consequences extend beyond the limited levels of infection in these cells. Here we
determined the relative efficiencies of HIV-1 binding and infection in human fetal astrocytes (HFA),
mainly at the single cell level, using HIV-1 tagged with green fluorescence protein (GFP)-Vpr fusion
proteins, termed HIV-GFP, to detect virus binding and HIV-1 expressing Rev and NefGFP fusion
proteins to detect productive infection.
Results: Essentially all HFA in a population bound HIV-GFP specifically and independently of CCR5
and CXCR4. The dynamics of this binding at 37°C resembled binding of an HIV fusion mutant to
CD4-positive cells, indicating that most of HIV-GFP arrested infection of HFA at the stage of virus-
cell fusion. Despite extensive binding, only about 1% of HFA were detectably infected by HIV-
RevGFP or HIV-NefGFP, but this proportion increased to the majority of HFA when the viruses
were pseudotyped with vesicular stomatitis virus envelope glycoprotein G, confirming that HFA
impose a restriction upon HIV-1 entry. Exposure of HFA to HIV-1 through its native proteins
rapidly induced synthesis of interleukin-6 and interleukin-8 with increased mRNA detected within
3 h and increased protein detected within 18 h of exposure.
Conclusion: Our results indicate that HIV-1 binding to human astrocytes, although extensive, is
not generally followed by virus entry and replication. Astrocytes respond to HIV-1 binding by
rapidly increased cytokine production suggesting a role of this virus-brain cell interaction in HIV-1
neuropathogenesis.
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Background
Human immunodeficiency virus type 1 (HIV-1) infection
is associated with a spectrum of neurological diseases of
varying severity including the endstage syndrome HIV-
associated dementia (HAD) [1]. Although the core patho-
physiological defects of HAD are neuronal damage and
loss of specific neuronal populations [1-4], neurons rarely
show evidence of HIV-1 infection [5-7]. It is generally
accepted that HIV-1 can be neuropathogenic through syn-
thesis of viral proteins that are directly neurotoxic as well
as through an array of cellular toxins that are produced by
HIV-1-infected cells (reviewed in [8,9]). Particularly in the
case of HAD with encephalitis, it is clear that HIV-1-
infected macrophages contribute greatly to disease
(reviewed in [8,10,11]). In various model systems and in
HIV-1-infected humans, multiple products of macro-
phages have been associated with neuropathogenesis
including arachidonic acid metabolites, IL-6, MCP-1,
platelet activating factor, and TNF-α [12-16].
There is growing interest in the potential role of astrocytes
in HIV-1-mediated neuropathogenesis. Astrocytes are an
abundant [17] and heterogeneous [18,19] population of
cells of neuroectodermal origin which perform many
essential functions in the brain, from structural and meta-
bolic support, responses to brain injury and innate
immune reactions, control of extracellular glutamate, to
regulation of neuronal cell activities and neural signaling
(reviewed in [20-23]). Astrogliosis, the presence of acti-
vated and hypertrophied astrocytes, is a defining neu-
ropathological characteristic of HAD [24,25]. There is also
evidence of HIV-1 infection in a small and variable frac-
tion of astrocytes in vivo, particularly in advanced brain
disease [7,26-30]. The significance of these overt astroglial
pathologies is unknown but overall, unlike neurons,
astrocytes rarely die in HIV-1-infected brains [31,32]. Pro-
ductive infection of human astrocytes with HIV-1 has sig-
nificant effects on cell physiology in vitro [33,34] and it
associates with measurable neuropathology in a mouse
model [35], suggesting that infected astrocytes, although
infrequent, can have localized pathogenic effects.
Growing evidence suggests that astrocytes also may suffer
dysregulation in the HIV-1-infected brain that may extend
beyond the limited levels of HIV-1 infection and contrib-
ute to neuropathogenesis in distinct pathways (reviewed
in [21,36-38]). As part of brain parenchyma, astrocytes are
likely exposed continuously to HIV-1 particles, viral pro-
teins, cytokines, and other substances secreted by HIV-1-
infected macrophages and microglia. Although they lack
CD4 they express CXCR4, and under certain circum-
stances, CCR3 and CCR5, the co-receptors for HIV-1 entry
into cells (reviewed in [39-41]). These chemokine recep-
tors can transduce responses to chemokines and to HIV-1
gp120 present in the brain and they might be involved in
HIV-1 association with astrocytes. Studies in vitro indicate
that many of these products significantly modulate astro-
cyte physiology which in turn can alter essential interac-
tions of astrocytes with other cells in the brain,
particularly neurons. For example, exposure of cultured
astrocytes to HIV-1, recombinant gp120, or viral transac-
tivator Tat induces some of the same secretable mediators
of neuropathogenesis as those produced by macrophages,
including inflammatory cytokines TNF-α and IL-1β,
chemokines MCP-1 and IP-10, IL-6, or neurotoxin nitric
oxide [42-50]. The apparent dysregulation of astrocyte
immune functions could contribute to the overall inflam-
matory environment in the brain. In other studies in cul-
ture, intact HIV-1 or exogenous gp120-induced extensive
changes in astrocyte gene expression [38,51-53] and
impaired transport of extracellular glutamate by astrocytes
[54,55], a defect which may lead to neuronal death by
glutamate excitotoxicity [20]. Glutamate uptake can also
be impaired by intracellular expression of recombinant
Tat or exposure of astrocytes to TNF-α [56,57]. In another
potential neurotoxic mechanism, recombinant gp120 was
shown to induce Ca++-dependent glutamate secretion by
astrocytes and neuronal cell death in glial-neuronal co-
cultures in a pathway involving signaling through CXCR4
and production of TNF-α [58,59]. Overall, these findings
suggest that astrocytes rendered dysfunctional by expo-
sure to HIV-1 in the brain have the capacity to injure or
impair neurons. Because both HIV-1 binding and native
infection can affect astrocyte function in vitro and in vivo
[33,35,55], astrocytes have a pathogenic potential that
exceeds their susceptibility to HIV-1 infection.
The interaction of HIV-1 with astrocytes is somewhat par-
adoxical. Astrocytes do not express surface CD4 but can
bind gp120 with high affinity through an unidentified
receptor [60,61]. Although exposure to virus or gp120 can
globally alter astrocyte function [53-55], HIV-1 infection
is highly inefficient compared to T lymphocytes [62-64], a
defect which can be attributed to poor virus entry [65-67].
We performed the present study to directly examine the
dichotomy between HIV-1 binding and infection in astro-
cytes, in part by analysis at the single cell level. We con-
structed several HIV-1 species that either carry or express
GFP fused to viral proteins to evaluate binding and infec-
tion of primary HFA by fluorescence microscopy. We also
used HIV-1 pseudotyped with the envelope glycoprotein
G of vesicular stomatitis virus (VSV-G) to efficiently infect
CD4-negative HFA [66] to compare productive infection
to virus binding for induction of cellular genes. Our
results demonstrate that virtually all HFA bind HIV-1 spe-
cifically, remarkably stably, and independently of the
chemokine receptors CCR3, CCR5, and CXCR4. As previ-
ously reported [68,69], fewer than 1% of HFA were sus-
ceptible to HIV-1 infection, but in contrast to some
previous studies [70] efficiently expressed Rev-dependentBMC Neuroscience 2007, 8:31 http://www.biomedcentral.com/1471-2202/8/31
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viral RNA and cognate protein. Finally we show that HIV-
1 binding to HFA through gp120 is necessary and suffi-
cient to rapidly induce IL-6 and increase expression of IL-
8. Our findings provide strong support for a robust path-
way of neuropathogenesis following frequent binding of
HIV-1 to astrocytes.
Results
Specific and extensive binding of HIV-1 by HFA
In previous studies we inferred that HIV-1 interacts with
the majority of HFA because exposure to intact or UV-
inactivated virus, or recombinant gp120 alone, reduced
glutamate uptake by cells and altered cellular gene expres-
sion on a population-wide basis [51,71], however such
findings are indirect. Using an approach developed by
McDonald and colleagues [72], we prepared fluores-
cently-labeled infectious virions by co-transfection of
plasmids encoding intact HIV-1/NL4-3 and a GFP-Vpr
fusion protein that is efficiently encapsidated [72] and
evaluated this HIV-GFP binding to HFA by fluorescence
microscopy. To investigate the specificity of the virus-cell
binding, astrocytes were exposed to HIV-GFP in the pres-
ence of either unlabeled virus or recombinant soluble
CD4 (sCD4) to compete for virion gp120 (Fig. 1). Essen-
tially all HFA bound HIV-1 and this binding was com-
pletely blocked by both competitors. To validate our
method and reagents, similar studies were carried out
with CD4-negative HeLa cells or with MAGI cells, a HeLa
derivative engineered to express human CD4 [73] (Fig. 2).
HeLa cells failed to bind HIV-1 but MAGI cells bound
virus and this inhibition was sensitive to competition by
sCD4, indicating that the evaluation of GFP-Vpr-labeled
virus binding by microscopy is reliable. These experi-
ments were repeated three times with similar results. We
also quantified binding on a population-wide basis by
measuring cell-associated p24 1 h after HIV-1 exposure to
cells at 4°C (Fig. 3). The extent of binding is expressed rel-
ative to the amount of p24 bound to HFA. MAGI cells
bound roughly 40% p24 bound to HFA, while CD4-neg-
ative 293T or HeLa cells bound less than 15% as much
p24 as did HFA. We also exposed HFA to antibodies to the
chemokine receptors CCR3, CCR5, or CXCR4, which have
been variably detected on HFA [74,75], to test whether
any of these receptors are involved in HFA binding of HIV-
1. There was a modest increase of virus binding after cells
were pretreated with anti-CXCR4; the other antibodies
had no effect. Taken together our studies demonstrate that
HIV-1 labeled through GFP-Vpr interacts specifically with
human cells and that the vast majority of HFA are compe-
tent to bind HIV-1. Competitors for gp120 block HIV-1
binding to HFA, confirming the specificity of the interac-
tion of HIV-1 with HFA, however our studies do not iden-
tify the cellular receptor.
Extent and specificity of HIV-1 binding to CD4-positive and  negative HeLa cells Figure 2
Extent and specificity of HIV-1 binding to CD4-posi-
tive and negative HeLa cells. CD4-positive MAGI cells 
were exposed for 1 h at 4°C to NL4-3 carrying GFP-Vpr 
alone (first row) or in the presence of soluble CD4 (second 
row). CD4-negative HeLa cells were exposed to HIV-1/NL4-
3 carrying GFP-Vpr (third row). Cells were stained with anti-
β actin and a Texas Red-labeled secondary antibody and 
DAPI and images of red and green fluorescence were super-
imposed (third column).
β-actin GFP                      β-actin+GFP
MAGI:
HIV-GFP
MAGI:
HIV-GFP
+sCD4
HeLa:
HIV-GFP
Extent and specificity of HIV-1 binding to HFA Figure 1
Extent and specificity of HIV-1 binding to HFA. Pri-
mary HFA were exposed for 1 h at 4°C to NL4-3 carrying 
GFP-Vpr alone (first row), in the presence of excess unla-
beled NL4-3 (second row) or in the presence of soluble CD4 
(third row). Cells were stained with anti-GFAP and a Texas 
Red-labeled secondary antibody to label astrocytes and with 
DAPI to visualize nuclei. Images of red and green fluores-
cence were superimposed (third column).
GFAP                         GFP                       GFAP+GFP
HIV-GFP
HIV-GFP
+HIV
HIV-GFP
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HIV-1 internalizes poorly in HFA compared to CD4-
positive cells
HIV-1 binding to CD4-bearing lymphocytes is rapidly fol-
lowed by virus-cell fusion and internalization of the viral
nucleocapsid [76]. Since it appears that HFA universally
bind HIV-1 (Figs. 1, 2, 3) but they permit limited virus
infection [63,64], one defect may lie in post-binding
events leading to virus entry. To investigate the internali-
zation of HIV-1 by HFA, we exposed HFA or MAGI cells to
HIV-GFP in culture at 37°C for various periods of times
prior to fixation and observation by fluorescence micros-
copy (Fig. 4). As a negative control in these studies, we
employed 517B-GFP, a mutant of HIV-1 able to bind to
but not fuse with cells [77]. HIV-GFP was detected on the
surface of both HFA and MAGI cells 1 h after exposure but
subsequently the progress of virus-cell interaction in the
two cell types diverged. By 6 h after exposure the virus was
internalized into MAGI cells and appeared to colocalize or
overlay intracellular actin; 18 h after exposure no fluores-
cent signal was detected in MAGI cells, indicating intracel-
lular breakdown of GFP-Vpr (top panel in Fig. 4). In
contrast, bright green fluorescence was detected on astro-
cytes throughout the 18 h incubation, a staining pattern
very similar to that observed with MAGI cells exposed to
fusion-incompetent 517B-GFP (middle and bottom pan-
els in Fig. 4). Longer follow up studies revealed that HIV-
GFP remains associated with HFA for up to 48 h after ini-
tial exposure without significant loss of the fluorescence
signal (data not shown). Similar results were obtained in
three independent experiments. These results indicate that
HIV-1 binds efficiently and stably to the majority of cells
in our HFA cultures and that most of the HFA-bound
virus, unlike that bound to MAGI cells, fails to internalize.
We cannot definitively localize the GFP-labeled virions by
the microscopy method used, but by analogy to fusion-
deficient 517B (Fig. 4), one possible reason for inefficient
entry of HIV-1 into HFA is that virion binding is not fol-
lowed by virus-cell fusion, at least for the bulk of virus vis-
ualized by our binding method. Under the conditions of
these experiments, virion phagocytosis by HFA [78] was
not detected but it cannot be excluded.
HIV-1 expression occurs in a small subset of HFA
Previous studies have shown that HIV-1-infected astro-
cytes express high levels of regulatory viral proteins such
as Rev or Nef [27,63] indicating the utility of these protein
markers of astrocyte infection. Therefore, to facilitate
detection of HIV-1 expressing HFA, we constructed either
NL4-3 or fusion-incompetent 517B with genes encoding
fusion proteins of GFP with either Nef or Rev to visualize
HIV-1 infections at the single cell level in HFA. An addi-
tional advantage of these constructs was that since these
proteins are not carried in virions, their detection requires
new viral protein synthesis by infected cells. HFA were
Dynamics of GFP-Vpr/HIV-1 association with HFA or MAGI  cells at 37°C Figure 4
Dynamics of GFP-Vpr/HIV-1 association with HFA or 
MAGI cells at 37°C. MAGI cells were exposed to NL4-3 
carrying GFP-Vpr (first row) or to the fusion incompetent 
HIV-1/517B carrying GFP-Vpr (second row) or HFA were 
exposed to NL4-3-GFP-Vpr. Cells were incubated with virus 
at 37°C and fixed at 1 h (first column), 6 h (second column), 
or 18 h (third column) after infection. HeLa cells were 
stained with anti-actin and HFA were stained with anti-
GFAP, with DAPI and with Texas Red-labeled secondary 
antibodies. Images shown are superimpositions of red and 
green fluorescence.
1h                              6h                             18h
MAGI:
HIV-GFP
MAGI:
517B-GFP
HFA:
HIV-GFP
Quantitation and specificity of HIV-1 binding to HFA Figure 3
Quantitation and specificity of HIV-1 binding to HFA. 
HFA were exposed for 1 h at 4°C to NL4-3 alone or in the 
presence of anti-CCR3, anti-CCR5, or anti-CXCR4 antibod-
ies. For comparison, CD4-negative HeLa or 293T cells or 
CD4-positive MAGI cells were also exposed to NL4-3. HIV-
1 binding, as determined by the amount of p24 core antigen 
associated with cells, was measured by ELISA. Data are 
expressed relative to HFA.
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infected by HIV-NefGFP or HIV-RevGFP or by VSV-G
pseudotyped HIV-1 carrying NefGFP and infected cells
were examined by fluorescence microscopy 48 h later (Fig.
5A). Consistent with our previous study [66], the bulk of
HFA could be productively infected by VSV-G pseudo-
typed HIV-1 as shown in the detection of NefGFP. In con-
trast, only about 1% of HFA expressed NefGFP after
infection by HIV-1 using its native envelope protein,
gp120. To address the issue of the relative expression of
structural versus regulatory genes, HFA were infected with
virus encoding RevGFP and then were stained for expres-
sion of p24 (lower panel in Fig. 5A). All cells that
expressed RevGFP also expressed p24 indicating no defect
in Rev functions or structural gene expression. To validate
this approach, a similar experiment was performed using
CD4-positive MAGI cells and the fusion-mutant 517B
(Fig. 5B). NefGFP was efficiently expressed after NL4-3
infection but not after 517B expression, indicating that
Nef detection required virus entry and synthesis of viral
protein. Expression of NefGFP by 517B could be rescued
by pseudotyping with VSV-G (lower panel in Fig. 5B), in
direct analogy to studies with HFA in Fig. 5A, and con-
firming that the 517B mutation in gp41 prevents the
mutant virus internalization and expression [77]. Similar
results were obtained in three independent experiments.
These results support the interpretation that NefGFP
expression is suitable for detection of de novo viral protein
synthesis as described for HFA in Fig. 5A.
Induction of cytokines by exposure of HFA to HIV-1
Previous studies have shown that viral envelope protein
gp120 can induce a range of neuroinflammatory products
in primary astrocytes in culture [46,79], but intact HIV-1
was tested of this activity only in transformed cell lines
[43,80]. Here we tested whether HIV-1, consistent with its
ability to efficiently bind to HFA, can induce expression of
any of a panel of cytokines and chemokines detectable by
multi-protein blots (Fig. 6A–C). Culture supernatants
from HFA 24 h after mock infection, infection with VSV-
G pseudotyped NL4-3 that carries an incapacitating muta-
tion in gp120 (VSV/NL4-3), and infection with native
HIV-1/NL4-3 all contained IL-8, but the chemokine
expression was increased by VSV/NL4-3 and native HIV-1
exposure. In contrast, IL-6 was only detected after expo-
sure of astrocytes to native HIV-1 (Fig. 6C). To investigate
the virus specificity of the IL-6 response, we exposed HFA
to X4 NL4-3; CM235, an R5 HIV-1; or VSV/NL4-3 and
then tested the expression of IL-6 by ELISA (Fig. 6D). Both
the X4 and the R5 HIV-1-induced IL-6 protein expression.
However the replication competent VSV/NL4-3 (which
lacks gp120) failed to induce IL-6 within the test time
frame, strongly suggesting that gp120 binding and no
other HIV-1 function was the initiator of the IL-6
response. To determine the kinetics of the observed
responses to HIV-1, HFA were mock-infected or infected
by NL4-3 and at time increments between 1 h and 12 h
cells were harvested for quantitative real-time PCR assay
of their levels of IL-6 and IL-8 transcripts (Fig. 6E). The
RNA measurements were standardized by the levels of
glyceraldehyde phosphate dehydrogenase RNA and data
are expressed as fold change relative to cells harvested at 0
time, immediately prior to infection or mock infection
(Fig. 6E). Both transcripts were induced rapidly after HIV-
Expression of HIV-1 regulatory and structural genes by  infected HFA and control cells Figure 5
Expression of HIV-1 regulatory and structural genes 
by infected HFA and control cells. A) HFA were 
infected with VSV-G pseudotyped NL4-3 encoding a NefGFP 
fusion protein (first row), with native NL4-3 encoding Nef-
GFP (second row) or encoding RevGFP (third row). Two 
days after infection HFA were stained using specific antibod-
ies for GFAP (first and second rows) or p24 (third row) and 
with DAPI and Texas Red-labeled secondary antibodies. 
Images of red and green fluorescence were superimposed 
(third column). B) MAGI cells were infected with NL4-3 
encoding NefGFP (first row), or fusion incompetent 517B 
encoding NefGFP (second row), or 517B-NefGFP pseudo-
typed by VSV-G (third row). Two days after infection cells 
were stained with anti-actin, DAPI, and Texas Red-labeled 
secondary antibody and images of red and green fluores-
cence were superimposed (third column).
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1 exposure and then declined by 9–12 h. In contrast in
mock-infected cells IL-6 expression was slightly reduced in
culture and IL-8 expression increased 15-fold after 3 h in
culture, the latter consistent with the results of multi-pro-
tein blots (Fig. 6A–C). Similar results were obtained in at
least seven independent experiments utilizing different
preparations of astrocytes and different virus batches.
These results indicate that the near-universal binding of
HIV-1 to HFA results in a rapid induction of expression of
two arms of innate immunity, interferon-based and
chemokine-based.
Discussion
The results presented here reveal a new basis for func-
tional responses of astrocytes to HIV-1. We show that
effectively all of the cells in cultured fetal astrocyte popu-
lations bind HIV-1 but only a small minority of cells per-
mits HIV-1 infection. HIV-1 binding is sufficient to trigger
rapid synthesis of IL-6, one of the major innate immune
effectors associated with HIV-1 neuropathogenesis [13]
and it increases the expression of IL-8, a potent chemok-
ine [81]. These results suggest that HIV-1 affects astrocyte
physiology on a cell population-wide basis primarily
through binding to cells and binding-induced signaling,
rather than infection.
Resolution at the single cell level permitted us to draw
these conclusions. We employed a GFP-Vpr tagged "green
HIV-1" [72] and infectious HIV-1 expressing Rev- or Nef-
GFP fusion proteins to assess the relative efficiency of
virus binding, entry, and expression by fluorescence
microscopy. Binding was clearly the most pronounced
step of HIV-1 interaction with astrocytes. HIV-1 bound to
the majority of astrocytes in our cell cultures, similar to its
interaction with CD4-positive cells as visualized by micro-
scopy and exceeding binding to some CD4-positive cells
as measured by p24 association (Figs. 1 and 3). The bind-
ing observed was specific as indicated in its competition
with excess unlabeled virus (Fig. 1) and the absence of
binding to unrelated CD4-negative cells (Figs. 2 and 3).
The HIV-1 interaction with astrocytes is likely to be medi-
ated by the viral envelope glycoprotein gp120 because
preincubation of GFP-Vpr tagged virions with soluble
CD4 prevented HIV-1 binding in our study (Fig. 1) and it
was shown to block astrocyte infection by HIV-1 in a pre-
vious report [61]. Furthering supporting this conclusion,
another study demonstrated that recombinant gp120
binds to a single-class binding site on human fetal astro-
cytes and that the affinity of this interaction approaches
that of the gp120-CD4 binding [60]. Taken together, our
results directly show that, like human T lymphocytes and
macrophages, human astrocytes can be classified as a cell
type fully competent to bind HIV-1. We do not know at
present whether adult astrocytes exhibit similar HIV-1
binding characteristics as fetal cells used in the present
work, but it should be noted that fetal astrocytes are an
acceptable model for study of many receptor-ligand inter-
actions including those with neurotransmitters, cytokines,
and growth factors [57,82,83]. Given the size of the astro-
glial compartment [17], our findings raise the possibility
that astrocytes present a major target for absorbing HIV-1
and gp120 produced in HIV-1-infected brain.
The cell surface receptor(s) responsible for HIV-1 binding
to astrocytes has not been conclusively identified
although several candidate proteins have been described
[78,84]. CD4 serves as the binding receptor for HIV-1 on
T lymphocytes and macrophages and binding to CD4
facilitates binding to co-receptors required for virus-cell
fusion [85]. Astrocytes do not express CD4 [60] but have
been shown to variously display viral co-receptors includ-
ing CCR3, CCR5, and CXCR4 [74,75] and in some other
systems the viral co-receptor is sufficient to bind immun-
odeficiency viruses. CD4-independent HIV-2 and SIV
have shown to bind and enter T cells through CXCR4
[86,87] and the major receptor for some FIV on T cells
appears to be CXCR4 [88]. Nevertheless, monoclonal
antibodies that bind CXCR4, CCR3, or CCR5 did not
block HIV-1 binding to HFA. Indeed anti-CXCR4 treat-
ment slightly enhanced HIV-1 binding. A more recent
study identified the chemokine receptor D6 as a receptor
Induction of cytokines by exposure of HFA to HIV-1 Figure 6
Induction of cytokines by exposure of HFA to HIV-1. 
A-C) HFA were mock-infected (panel A); infected with VSV/
NL4-3, a VSV-G pseudotyped NL4-3 incapable of expressing 
gp120 (panel B), or infected with NL4-3 (panel C), washed, 
and after 24 h incubation cell supernatants were collected 
and applied to RayBio Human Cytokine Antibody Array 3.1. 
The map of antibodies present on the array can be accessed 
at http://www.raybiotech.com/map/human_III_map.pdf. D) 
HFA were infected as indicated, washed, and after 24 h incu-
bation supernatants were collected for assay of IL-6 levels by 
ELISA. E) The expression of IL-6 (upper panel) and IL-8 
(lower panel) mRNA by HFA was measured by qPCR at the 
indicated times after mock infection or NL4-3 infection.
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on HFA for certain HIV-1 and HIV-2 clones, but NL4-3
that we employed here could not enter HFA via D6 [84].
These results rule out these chemokine receptors as the
major receptors for HIV-1/NL4-3 on HFA but leave open
the identity of the receptor.
Compared to T lymphocytes and macrophages, astrocytes
undergo only limited infection with HIV-1 in vitro and in
vivo [7,27,28,63,64]. Explanations advanced by our labo-
ratory and others include inefficient virus entry [65-67]
and intracellular restrictions to HIV-1 expression [63,89].
This work further clarifies the relative contributions of
these mechanisms. By analysis at the single cell level we
show that the majority of astrocytes in our cell popula-
tions are refractory to HIV-1 infection despite universal
binding of virus to HFA (Figs. 1 and 5). We attribute this
disparity to inefficient virus entry into the majority of
astrocytes that bind HIV-1. The block at entry was indi-
cated by i) different dynamics of HIV-GFP association
with HFA and CD4-positive cells at 37°C as visualized by
fluorescence imaging; ii) the similarity between GFP-Vpr
tagged NL4-3 and entry-defective 517B viruses in their
respective target cell associations by the same method;
and iii) the demonstration at a single cell level that cir-
cumventing restricted HIV-1 entry by use of VSV-G pseu-
dotyped virus permits efficient infection of HFA, as also
shown by cell population analyses in our previous studies
[33,34,66] and consistent with other reports
[34,67,84,90]. The 517B construct of HIV-1 contains a
mutation in the fusion domain of gp41 that incapacitates
virus-cell fusion and virus entry [77]. Based on analogy
with 517B revealed here, HIV-1 binding to HFA may not
generally be followed by virus-cell fusion, resulting in
inefficient entry in most of the cells exposed to the virus.
The mechanism of HIV-1 entry into the minority of HFA
that permit virus infection is also uncertain at present,
although at least one study suggested it is by endocytosis
mediated by a mannose receptor [78].
Although GFP-Vpr tagged HIV-1 is a useful tool to investi-
gate initial virus-cell interactions it is not suitable for enu-
merating the fraction of astrocyte that does permit virus
infection because it does not encode GFP. We used for
that purpose infectious HIV-1 expressing RevGFP and
NefGFP fusion proteins. Other investigators have also
employed RevGFP constructs to investigate its function on
astrocytes outside HIV-1 infection [91]. RevGFP and Nef-
GFP are not subject to the proposed intracellular restric-
tions to HIV-1 replication in astrocytes [63,89] and thus
their detection accurately marks all HFA in our cell popu-
lations that allow virus entry and expression. We found
that Rev and Nef were expressed only in a small fraction
of cells, about 1% (Fig. 5), consistent with previous
reports [68,69]. Of note, the HIV-RevGFP-infected astro-
cytes also expressed p24 in double-label analysis (Fig. 5).
This indicates that some astrocytes may permit comple-
tion of the HIV-1 replicative cycle, at least during acute
infection and consistent with our studies with VSV-G/HIV
and some other reports [33,66,67,84,90]. However, our
studies do not exclude the possibility that following tran-
sition to chronic infection astrocytes may impose some
restrictions on HIV-1 expression, as indicated by estab-
lishment of inducible HIV-1 latency in chronically
infected HFA in vitro [92] and limited HIV-1 expression by
infected cells in vivo [7]. Regardless of the mechanism of
long-term HIV-1 infection in astrocytes, our work makes
clear that only a small fraction of HFA competent to bind
HIV-1 is susceptible to HIV-1 entry and expression at any
given time. It is unknown at present whether HIV-1 infects
cells randomly or it targets some yet undefined astrocyte
subpopulation [18,19]. More research is needed to iden-
tify HIV-1 susceptible cells in order to understand the
pathogenic potential of this infection.
In addition, binding of HIV-1 through gp120 has func-
tional consequences for HFA as previously reported
[54,55] and as shown here. Our results demonstrate that
HFA can be triggered to IL-6 expression by HIV-1 binding
but that HIV-1 infection by VSV-G/pseudotyped, gp120-
negative virus capable of expressing all other viral genes
cannot trigger this gene expression. These findings indi-
cate that gp120 binding and no other viral function acti-
vated IL-6 expression, at least in this 24 h exposure period.
Indeed, the induction of the IL-6 transcript was maximal
at the first time point tested, 1 h after virus exposure. IL-8
induction peaked somewhat later, at 3 h after exposure.
Previous studies have shown that HIV-1 Tat can activate
astrocytes to IL-8 production, although the activation was
about 10-fold less than that observed here [44]. Because
we find a small minority of cells susceptible to HIV-1
infection, it is more likely that the IL-8 expression
observed here resulted from gp120 binding to HFA than
from virus replication and Tat production. IL-8 is a major
chemotactic factor for a variety of leukocytes [81] and
increased IL-6 in the central nervous system has been
associated with brain disease in SIV-infected macaques
and has been implicated as a critical controlling element
in brain disease in the SIV-macaque model [13,93]. Our
observation raises the possibility that exposure of astro-
cytes in the brain to HIV-1 or to gp120 is responsible for
the observed increase in this key antiviral cytokine, inde-
pendently of virus replication in the brain. If the results
reported here faithfully reproduce the behavior of astro-
cytes in the brain, then this numerous and essential brain
cell type is exquisitely responsive to HIV-1 and its
responses may be a major factor in HIV-1 neuropathogen-
esis.BMC Neuroscience 2007, 8:31 http://www.biomedcentral.com/1471-2202/8/31
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Conclusion
Our results indicate that HIV-1 binding to human astro-
cytes, although extensive, is not generally followed by
virus entry and replication. Astrocytes respond to HIV-1
binding by rapidly increased cytokine production suggest-
ing a role of this virus-brain cell interaction in HIV-1 neu-
ropathogenesis.
Methods
Plasmid construction
pEGFP-Vpr plasmid was obtained from Dr. T. Hope
(Northwestern University). To generate the vector encod-
ing infectious NL4-3 expressing NefGFP, the wild-type
HIV-1 pNL4-3 vector (from NIH AIDS Research and Ref-
erence Reagent Program, Germantown, MD) was PCR
amplified using the Pfu DNA polymerase (Stratagene, La
Jolla, CA) with primer pair 5'-CGATTAGTGAACGGATC-
CTTAG-3' and 5'-CTTGCTCACCATAGCG-
GCCGCCCACTTGCCACCCATCTTATA-3'; pGFP-C1 was
PCR amplified with primer pair 5'-ATGGGTGGCAAGT-
GGGCGGCCGCTATGGTGAGCAAGGGCGAG-3' and 5'-
GACGTCGCTCGAGTTACTTGTACAGCTCGTCC-3'. The
PCR products were run and separated on 1% agarose gel,
purified by Ultrafree-DA tubes (Millipore, Billerica, MA),
then used as template for PCR with primer pair 5'-CGATT-
AGTGAACGGATCCTTAG-3' and 5'-GACGTCGCTC-
GAGTTACTTGTACAGCTCGTCC-3'. The second round
PCR product which joined above two fragments (HIV-1
and GFP coding sequence) was ligated to BamH I and Xho
I sites of pNL4-3 plasmid. To generate vector HIV/
RevGFP, HIV-1/Lai (from NIH AIDS Research and Refer-
ence Reagent Program) was PCR amplified using the Pfu
DNA polymerase with primer pair 5'-CGATTAGTGAACG-
GATCCTTAG-3' and 5'-CTCGCCCTTGCTCACCATTTCTT-
TAGTTCCTGACTCCAA-3'; pGFP-C1 was PCR amplified
with primer pair 5'-TCAGGAACTAAAGAAATGGTGAG-
CAAGGGCGAGGAGCTG-3' and 5'-GACGTCGCTC-
GAGTTACTTGTACAGCTCGTCC-3'. The PCR products
were run and separated on 1% agarose gel, purified by
Ultrafree-DA tubes (Millipore), then used as template for
PCR with primer pair 5'-CGATTAGTGAACGGATCCT-
TAG-3' and 5'-GACGTCGCTCGAGTTACTTGTA-
CAGCTCGTCC-3'. The second round PCR product which
jointed above two fragments was ligated to BamH I and
Xho I sites of pHIV-1/Lai plasmid. The construction of all
of the above plasmids were confirmed by restriction
enzyme digestion or sequencing. The NL4-3-517B was
constructed by excising the envelope coding sequence
from pHXB2-517B [77], obtained from Dr. J. Sodroski,
Harvard Medical School, and inserting it into the Sal I and
BamH I sites of pNL4-3. Plasmid encoding infectious
CM235 [94] was kindly provided by Dr. P. Ehrenberg
(Walter Reed Army Institute of Research, Rockville, MD).
Cell culture, transfection and infection
HFA were isolated from second trimester human fetal
brains (gestational age 16–19 weeks) obtained from elec-
tive abortions in full compliance with National Institutes
of Health guidelines. Highly enriched HFA preparations
were obtained by high-density culture in the absence of
growth factors in F12 DMEM (Invitrogen, Carlsbard, CA)
containing 10% fetal bovine serum (FBS) and antibiotics
essentially as described [66]. The cells were propagated in
the same medium at 2–5 × 104 cells/cm2 and subcultured
weekly up to 4 times. Experiments were performed on
HFA in passage 3; at this stage >99% of cells stained posi-
tive for the astrocyte marker GFAP and no microglial con-
tamination was detectable by anti-CD68 staining (not
shown; [33,66]). 293T, HeLa and HeLa-CD4-LTR-βGal
(MAGI) cells were obtained from the NIH AIDS Research
and Reference Reagent Program; the cells were cultured in
DMEM supplemented with 10% FBS and penicillin-strep-
tomycin (100 U/ml). Transfections were performed by the
standard calcium phosphate precipitation method which
usually in our hands has over 50% transfection efficiency
in 293T cells. PBL from healthy donors were activated for
48 h with phytohemagglutinin (PHA) and were then cul-
tivated in RPMI 1640 medium supplemented with 10%
FBS. CEM cells were cultured in RPMI-1640 containing
10% FBS.
Concentration and purification of viral particles
To prepare HIV-GFP 293T cells were cotransfected with an
EGFP-Vpr and a designated HIV-1 plasmid and after two
days supernatant was collected and virus content deter-
mined using the HIV-1 Ag ELISA kit, Coulter, Hialeah, FL.
Alternatively, PBL were infected with different strains of
HIV-1, after 5 days, supernatant was collected, filtered
through 0.22-µm-pore-size filters, layered over a 20%
sucrose cushion in PBS, and centrifuged for 1 h at 20,000
× g. The viral pellet was washed once, resuspended in PBS,
and virus content was determined by p24 ELISA.
Determination of virus binding by measurement of cell-
associated p24
HFA, CD4-negative 293T or HeLa, and CD4-positive-
MAGI cells (2 × 105 cells/well in 12-well plates) were incu-
bated with indicated virus preparations at a dose of 1 pg
p24 per cell for 2 h at 4°C. This dose is equivalent to one
infectious unit (I.U.) per cell as determined by virus infec-
tivity assay in MAGI cells [73]. To evaluate inhibition of
virus binding, cells were exposed to human anti-CXCR4
(12G5), anti-CCR5 (5C7) or anti-CCR3 (7B11) mono-
clonal antibodies (NIH AIDS Research and Reference Rea-
gent Program) at 1 µg/ml for 30 min prior to virus
exposure at either 37°C or 4°C in a final volume of 500
µl and then exposed to virus for 1 h at 4°C. At the end of
the incubation period, cells were vigorously washed five
times with PBS to remove unabsorbed virus and lysedBMC Neuroscience 2007, 8:31 http://www.biomedcentral.com/1471-2202/8/31
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with 300 µl of PBS containing 0.5% NP40. The lysates
were cleared by centrifugation (10,000 × g for 5 min) and
the p24 content of the lysate was determined by ELISA.
The percentage of virus particles bound by cells was calcu-
lated by the following formula: [(pg p24 associated with
cells)/(pg input p24) × 100]. All virus binding or infection
assays were performed in duplicate or triplicate.
Determination of GFP-Vpr virus binding and entry by 
fluorescence microscopy and image analysis
For binding experiments, HFA, HeLa and MAGI cells were
grown in 12-well plates with round coverslips. Cells were
exposed to HIV-GFP virions at 1 pg viral p24 per cell for 1
h at 4°C. To compete for HIV-GFP binding, cells were
exposed to 10-fold excess of unlabeled NL4-3 virions for
1 h at 4°C prior to exposure to HIV-GFP virions. To
inhibit binding, HIV-GFP virions were pretreated with 20
µg/ml of soluble CD4 prior to incubation with cells.
Virus-cell mixtures were then washed five times with PBS
to remove unabsorbed virus; washed cells were fixed with
2% paraformaldehyde in PBS, stained with 1 ng/ml of
DAPI in methanol for detection of nuclei, stained with
primary antibodies, washed, stained with Texas Red
linked cognate secondary antibodies (Amersham, Piscata-
way, NJ), washed, air dried, and mounted in glass slides
with 50% glycerol in PBS. To follow virus internalization,
cells were exposed to HIV-GFP virions at 4°C for 1 h,
washed, supplemented with appropriate media, cultured
37°C for the designated periods of time, and fixed and
observed or stained as described above. Fluorescence
images were captured by using a digital video imaging
microscope system consisting of a Zeiss Model Axioplan 2
microscope (Carl Zeiss, Thornwood, NY) with a HAMA-
MATSU ORCA-ER digital camera (HAMAMATSU Corp,
Bridgewater, NJ) and Openlab software (Improvision,
Lexington, MA).
Human cytokine array
HFA were mock infected or incubated with designated
virus for 5 h at 37°C, cells were washed five times and cul-
tured in low serum medium overnight. Supernatant were
collected and incubated with the Human Cytokine Array
3.1 multiprotein blot (Ray Biotech, Norcross, GA) mem-
brane for 2 h at room temperature. After decanting the
samples from container, the membrane was washed three
times. Biotinylated anti-human cytokine antibodies were
added and incubated at room temperature for 2 h. This
was followed by washing, incubation with streptavidin
conjugated peroxidase, and visualization by enhanced
chemiluminescence system (Amersham).
Quantitative real-time RT-PCR (qPCR)
HFA were mock-infected or infected with 1 pg p24 per cell
of NL4-3, and RNA was extracted and cDNA was synthe-
sized as described above. qPCR was conducted as
described [95] using Taqman chemistry with human IL-6,
IL-8, and GAPDH probes and primers designed using
Primer Express v.1.0 (Applied Biosystems). PCR reaction
contained 5 µl of ABI 2× Universal Master Mix, 1.25 µl of
each forward and reverse primers at 200–900 nM, 1 µl of
probe at 50–200 nM, and RNAase/DNAase free water. All
reactions were performed in duplicate and were run in an
ABI 7500. Raw data were analyzed using the Sequence
Detection Software (ABI); relative quantitation employed
the comparative threshold cycle method (Applied Biosys-
tems Technical Bulletin #2). Signals were normalized to
signals of the levels of GAPDH transcripts and are pre-
sented as fold changes versus 0 time, with cells collected
before infection or mock infection.
IL-6 ELISA
The IL-6 protein level in cell growth medium was detected
by human IL-6 ELISA development system (R&D Systems
Inc, Minneapolis, MN). Briefly, 96-well plates were coated
with anti-human IL-6 monoclonal antibodies overnight,
samples were added to the designated wells with 100 µl
per well and incubated at RT for 2 h. Fluid was aspirated
and the wells were washed three times with washing
buffer. Then 100 µl biotinylated anti-human IL-6 was
added to each well and incubated at RT for 2 h. This was
followed by washing, incubation with streptavidin conju-
gated peroxidase and color development.
Antibodies and other reagents
Anti-capsid (HIV-1 p24) monoclonal antibody was
obtained from the NIH AIDS Research and Reference Rea-
gent Program. Anti-β-actin monoclonal antibody was pur-
chased from Sigma (St. Louis, MO). Anti-GFAP polyclonal
antibodies were purchased from DAKO Corporation
(Carpinteria, CA).
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